References
- Cash J. Folsom prison blues. With his hot and blue guitar. Nashville, TN: Sun Records; 1955.
- Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012;120:3173–3186.
- Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335–339.
- Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425–433.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
- Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538–543.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
- Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
- Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med 2005;352:536–538.
- Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433–1440.
- Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients?A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010;34:864–870.
- Steensma DP. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep 2011;6:136–144.
- Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodysplastic syndromes: where do we stand?Expert Rev Hematol 2013;6:397–410.
- Neukirchen J. Iron chelation in MDS: still a controversial issue. Leuk Res 2014;38:145–146.
- Chan LSA, Shapiro R, Buckstein R, et al. Initial transfusion intensity predicts survival in myelodysplastic syndrome. Leuk Lymphoma 2014;55:2296–2300.
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.